A Phase 2, Open-Label Trial to Examine Kidney Tissue-Specific Effects of Felzartamab in Adults with IgAN (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #INFO08-SA; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Exploratory endpoints include efficacy, kidney tissue–specific and peripheral biomarkers, intrarenal molecular profiles, and histology in protocol kidney biopsies obtained at Weeks 0, 36, and 104. This study will inform on the impact of felzartamab on mesangial IgA deposition, kidney tissue–specific and peripheral biomarkers, efficacy, and safety, and will help to further elucidate the durable, disease-modifying potential of felzartamab in IgAN."
Clinical • IO biomarker • P2 data • Glomerulonephritis • IgA Nephropathy • Renal Disease
|
|
Jonathan Barratt; Matthias Kretzler; Saif A. Alenizi; Donna Flesher; Millie Shah; Valeria Beckett; Noelle Griffin; Uptal D. Patel; Brian Schwartz; Richard A. Lafayette
|